Market Cap | 111.68M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -17.63M | Forward P/E | 70.00 | EPS next Y | - | 50D Avg Chg | -18.00% |
Sales | 279.64M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -52.00% |
Dividend | N/A | Price/Book | 0.49 | EPS next 5Y | - | 52W High Chg | -84.00% |
Recommedations | 2.00 | Quick Ratio | 2.32 | Shares Outstanding | 10.62M | 52W Low Chg | 7.00% |
Insider Own | 25.01% | ROA | -15.30% | Shares Float | 7.85M | Beta | -0.09 |
Inst Own | 14.27% | ROE | -8.77% | Shares Shorted/Prior | 7.95K/20.51K | Price | 0.70 |
Gross Margin | 47.60% | Profit Margin | -15.80% | Avg. Volume | 151,390 | Target Price | 60.00 |
Oper. Margin | -281.07% | Earnings Date | - | Volume | 232,840 | Change | 1.45% |
Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring device that offers COVID-19 testing solutions for professional use and home use. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; ACTOnco, a comprehensive test that helps clinicians choose the optimal treatment for all major solid tumors; ACTDrug+, a screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options; ACTLung, a test focused on biomarkers associated with lung cancer for targeted therapy; ACTFusion, a test that decodes 13 fusion genes and more than 350 transcripts to map drug options; and ACTCerebra, a genomic profiling service for solid tumors. It also offers ACTMonitor, a test that analyzes 50 forms of circulating tumor DNA in the bloodstream; and ACT Risk, a screening of 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.